Enteropathogenic Escherichia coli inhibits type I interferon- and RNase L-mediated host defense to disrupt intestinal epithelial cell Barrier function

Infection and Immunity

Volumn 82, Issue 7, 2014, Pages 2802-2814

  Long, Tiha M ^a   Nisa, Shahista ^a   Donnenberg, Michael S ^a   Hassel, Bret A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BETA INTERFERON; INTERFERON; NLED PROTEIN; RIBONUCLEASE L; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CACO 2 CELL LINE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENTEROPATHOGENIC ESCHERICHIA COLI; ENTEROPATHOGENIC ESCHERICHIA COLI INFECTION; GASTROINTESTINAL TRACT; GROWTH INHIBITION; HOST RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; INTESTINE INFECTION; INTESTINE MUCOSA PERMEABILITY; MEDIATOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TYPE III SECRETION SYSTEM;

CACO-2 CELLS; ENDORIBONUCLEASES; ENTEROPATHOGENIC ESCHERICHIA COLI; EPITHELIAL CELLS; ESCHERICHIA COLI PROTEINS; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-BETA; INTESTINAL MUCOSA;

EID: 84903149779     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00105-14     Document Type: Article

References (104)

1. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omore R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I, Nhampossa T, Acacio S, Biswas K, O'Reilly CE, Mintz ED, Berkeley LY, Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM. 2013. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382:209-222. http://dx.doi.org/10.1016/S0140-6736(13)60844-2.
2. McNamara BP, Koutsouris A, O'Connell CB, Nougayrede JP, Donnenberg MS, Hecht G. 2001. Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function. J. Clin. Invest. 107:621-629. http://dx.doi.org/10.1172/JCI11138.
3. Nougayrede JP, Fernandes PJ, Donnenberg MS. 2003. Adhesion of enteropathogenic Escherichia coli to host cells. Cell. Microbiol. 5:359-372. http://dx.doi.org/10.1046/j.1462-5822.2003.00281.x.
4. Guttman JA, Li Y, Wickham ME, Deng W, Vogl AW, Finlay BB. 2006. Attaching and effacing pathogen-induced tight junction disruption in vivo. Cell. Microbiol. 8:634-645. http://dx.doi.org/10.1111/j.1462-5822.2005.00656.x.
5. Schumann M, Kamel S, Pahlitzsch ML, Lebenheim L, May C, Krauss M, Hummel M, Daum S, Fromm M, Schulzke JD. 2012. Defective tight junctions in refractory celiac disease. Ann. N. Y. Acad. Sci. 1258:43-51. http://dx.doi.org/10.1111/j.1749-6632.2012.06565.x.
6. Hering NA, Schulzke JD. 2009. Therapeutic options to modulate barrier defects in inflammatory bowel disease. Dig. Dis. 27:450-454. http://dx.doi.org/10.1159/000233283.
7. Choi HJ, Kim J, Do KH, Park SH, Moon Y. 2013. Enteropathogenic Escherichia coli-induced macrophage inhibitory cytokine 1 mediates cancer cell survival: an in vitro implication of infection-linked tumor dissemination. Oncogene 32:4960-4969. http://dx.doi.org/10.1038/onc.2012.508.
8. Shen L. 2012. Tight junctions on the move: molecular mechanisms for epithelial barrier regulation. Ann. N. Y. Acad. Sci. 1258:9-18. http://dx.doi.org/10.1111/j.1749-6632.2012.06613.x.
9. Chiba H, Osanai M, Murata M, Kojima T, Sawada N. 2008. Transmembrane proteins of tight junctions. Biochim. Biophys. Acta 1778: 588-600. http://dx.doi.org/10.1016/j.bbamem.2007.08.017.
10. Aroeti B, Friedman G, Zlotkin-Rivkin E, Donnenberg MS. 2012. Retraction of enteropathogenic E. coli type IV pili promotes efficient host cell colonization, effector translocation and tight junction disruption. Gut Microbes 3:267-271. http://dx.doi.org/10.4161/gmic.19814.
11. Hanajima-Ozawa M, Matsuzawa T, Fukui A, Kamitani S, Ohnishi H, Abe A, Horiguchi Y, Miyake M. 2007. Enteropathogenic Escherichia coli, Shigella flexneri, and Listeria monocytogenes recruit a junctional protein, zonula occludens-1, to actin tails and pedestals. Infect. Immun. 75:565-573. http://dx.doi.org/10.1128/IAI.01479-06.
12. Zolotarevsky Y, Hecht G, Koutsouris A, Gonzalez DE, Quan C, Tom J, Mrsny RJ, Turner JR. 2002. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 123:163-172. http://dx.doi.org/10.1053/gast.2002.34235.
13. Zhang Q, Li Q, Wang C, Li N, Li J. 2012. Redistribution of tight junction proteins during EPEC infection in vivo. Inflammation 35:23-32. http://dx.doi.org/10.1007/s10753-010-9285-1.
14. Baruch K, Gur-Arie L, Nadler C, Koby S, Yerushalmi G, Ben-Neriah Y, Yogev O, Shaulian E, Guttman C, Zarivach R, Rosenshine I. 2011. Metalloprotease type III effectors that specifically cleave JNK and NF-kappaB. EMBO J. 30:221-231. http://dx.doi.org/10.1038/emboj.2010.297.
15. Newton HJ, Pearson JS, Badea L, Kelly M, Lucas M, Holloway G, Wagstaff KM, Dunstone MA, Sloan J, Whisstock JC, Kaper JB, Robins-Browne RM, Jans DA, Frankel G, Phillips AD, Coulson BS, Hartland EL. 2010. The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65. PLoS Pathog. 6:e1000898. http://dx.doi.org/10.1371/journal.ppat.1000898.
16. Tacket CO, Sztein MB, Losonsky G, Abe A, Finlay BB, McNamara BP, Fantry GT, James SP, Nataro JP, Levine MM, Donnenberg MS. 2000. Role of EspB in experimental human enteropathogenic Escherichia coli infection. Infect. Immun. 68:3689-3695. http://dx.doi.org/10.1128/IAI.68.6.3689-3695.2000.
17. Salazar-Gonzalez H, Navarro-Garcia F. 2011. Intimate adherence by enteropathogenic Escherichia coli modulates TLR5 localization and proinflammatory host response in intestinal epithelial cells. Scand. J. Immunol. 73:268-283. http://dx.doi.org/10.1111/j.1365-3083.2011.02507.x.
18. Khan MA, Ma C, Knodler LA, Valdez Y, Rosenberger CM, Deng W, Finlay BB, Vallance BA. 2006. Toll-like receptor 4 contributes to colitis development but not to host defense during Citrobacter rodentium infection in mice. Infect. Immun. 74:2522-2536. http://dx.doi.org/10.1128/IAI.74.5.2522-2536.2006.
19. Liu Z, Zaki MH, Vogel P, Gurung P, Finlay BB, Deng W, Lamkanfi M, Kanneganti TD. 2012. Role of inflammasomes in host defense against Citrobacter rodentium infection. J. Biol. Chem. 287:16955-16964. http://dx.doi.org/10.1074/jbc.M112.358705.
20. Wang F, Schwarz BT, Graham WV, Wang Y, Su L, Clayburgh DR, Abraham C, Turner JR. 2006. IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology 131:1153-1163. http://dx.doi.org/10.1053/j.gastro.2006.08.022.
21. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. 2005. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am. J. Pathol. 166:409-419. http://dx.doi.org/10.1016/S0002-9440(10)62264-X.
22. Matsuda M, Kubo A, Furuse M, Tsukita S. 2004. A peculiar internalization of claudins, tight junction-specific adhesion molecules, during the intercellular movement of epithelial cells. J. Cell Sci. 117:1247-1257. http://dx.doi.org/10.1242/jcs.00972.
23. Wong AR, Pearson JS, Bright MD, Munera D, Robinson KS, Lee SF, Frankel G, Hartland EL. 2011. Enteropathogenic and enterohaemorrhagic Escherichia coli: even more subversive elements. Mol. Microbiol. 80:1420-1438. http://dx.doi.org/10.1111/j.1365-2958.2011.07661.x.
24. Gao X, Wang X, Pham TH, Feuerbacher LA, Lubos ML, Huang M, Olsen R, Mushegian A, Slawson C, Hardwidge PR. 2013. NleB, a bacterial effector with glycosyltransferase activity, targets GAPDH function to inhibit NF-kappaB activation. Cell Host Microbe 13:87-99. http://dx.doi.org/10.1016/j.chom.2012.11.010.
25. Yen H, Ooka T, Iguchi A, Hayashi T, Sugimoto N, Tobe T. 2010. NleC, a type III secretion protease, compromises NF-kappaB activation by targeting p65/RelA. PLoS Pathog. 6:e1001231. http://dx.doi.org/10.1371/journal.ppat.1001231.
26. Nadler C, Baruch K, Kobi S, Mills E, Haviv G, Farago M, Alkalay I, Bartfeld S, Meyer TF, Ben-Neriah Y, Rosenshine I. 2010. The type III secretion effector NleE inhibits NF-kappaB activation. PLoS Pathog. 6:e1000743. http://dx.doi.org/10.1371/journal.ppat.1000743.
27. Kole A, He J, Rivollier A, Silveira DD, Kitamura K, Maloy KJ, Kelsall BL. 2013. Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis. J. Immunol. 191:2771-2779. http://dx.doi.org/10.4049/jimmunol.1301093.
28. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Forster I, Farlik M, Decker T, Du Pasquier RA, Romero P, Tschopp J. 2011. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34:213-223. http://dx.doi.org/10.1016/j.immuni.2011.02.006.
29. Guo B, Chang EY, Cheng G. 2008. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 118:1680-1690. http://dx.doi.org/10.1172/JCI33342.
30. McAleer JP, Kolls JK. 2012. Maintaining poise: commensal microbiota calibrate interferon responses. Immunity 37:10-12. http://dx.doi.org/10.1016/j.immuni.2012.07.001.
31. Monroe KM, McWhirter SM, Vance RE. 2010. Induction of type I interferons by bacteria. Cell. Microbiol. 12:881-890. http://dx.doi.org/10.1111/j.1462-5822.2010.01478.x.
32. Abt MC, Osborne LC, Monticelli LA, Doering TA, Alenghat T, Sonnenberg GF, Paley MA, Antenus M, Williams KL, Erikson J, Wherry EJ, Artis D. 2012. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 37:158-170. http://dx.doi.org/10.1016/j.immuni.2012.04.011.
33. Ganal SC, Sanos SL, Kallfass C, Oberle K, Johner C, Kirschning C, Lienenklaus S, Weiss S, Staeheli P, Aichele P, Diefenbach A. 2012. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity 37: 171-186. http://dx.doi.org/10.1016/j.immuni.2012.05.020.
34. Sainathan SK, Bishnupuri KS, Aden K, Luo Q, Houchen CW, Anant S, Dieckgraefe BK. 2012. Toll-like receptor-7 ligand imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis. Inflamm. Bowel Dis. 18:955-967. http://dx.doi.org/10.1002/ibd.21867.
35. Li XD, Chiu YH, Ismail AS, Behrendt CL, Wight-Carter M, Hooper LV, Chen ZJ. 2011. Mitochondrial antiviral signaling protein (MAVS) monitors commensal bacteria and induces an immune response that prevents experimental colitis. Proc. Natl. Acad. Sci. U. S. A. 108:17390-17395. http://dx.doi.org/10.1073/pnas.1107114108.
36. Wang Y, Zhang HX, Sun YP, Liu ZX, Liu XS, Wang L, Lu SY, Kong H, Liu QL, Li XH, Lu ZY, Chen SJ, Chen Z, Bao SS, Dai W, Wang ZG. 2007. Rig-I-/-mice develop colitis associated with downregulation of G alpha i2. Cell Res. 17:858-868. http://dx.doi.org/10.1038/cr.2007.81.
37. Cao SS, Song B, Kaufman RJ. 2012. PKR protects colonic epithelium against colitis through the unfolded protein response and prosurvival signaling. Inflamm. Bowel Dis. 18:1735-1742. http://dx.doi.org/10.1002/ibd.22878.
38. Sumer N, Palabiyikoglu M. 1995. Induction of remission by interferonalpha in patients with chronic active ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 7:597-602.
39. Baert F, Rutgeerts P. 1995. Interferon-alpha: an efficacious immunemodulating therapy for ulcerative colitis? Eur. J. Gastroenterol. Hepatol. 7:593-594.
40. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603-606. http://dx.doi.org/10.1038/35079114.
41. Strober W, Kitani A, Fuss I, Asano N, Watanabe T. 2008. The molecular basis of NOD2 susceptibility mutations in Crohn's disease. Mucosal Immunol. 1(Suppl. 1):S5-S9. http://dx.doi.org/10.1038/mi.2008.42.
42. Pott J, Hornef M. 2012. Innate immune signalling at the intestinal epithelium in homeostasis and disease. EMBO Rep. 13:684-698. http://dx.doi.org/10.1038/embor.2012.96.
43. Xavier RJ, Podolsky DK. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427-434. http://dx.doi.org/10.1038/nature06005.
44. MacMicking JD. 2012. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat. Rev. Immunol. 12:367-382. http://dx.doi.org/10.1038/nri3210.
45. Long TM, Chakrabarti A, Ezelle HJ, Brennan-Laun SE, Raufman JP, Polyakova I, Silverman RH, Hassel BA. 2013. RNase-L deficiency exacerbates experimental colitis and colitis-associated cancer. Inflamm. Bowel Dis. 19:1295-1305. http://dx.doi.org/10.1097/MIB.0b013e318281f2fd.
46. Solis M, Goubau D, Hiscott J. 2007. RIG-I has guts: identification of a role for RIG-I in colitis development. Cell Res. 17:974-975. http://dx.doi.org/10.1038/cr.2007.107.
47. Malathi K, Dong B, Gale M, Jr, Silverman RH. 2007. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 448: 816-819. http://dx.doi.org/10.1038/nature06042.
48. Zhou A, Hassel BA, Silverman RH. 1993. Expression cloning of 2-5Adependent RNAase: a uniquely regulated mediator of interferon action. Cell 72:753-765. http://dx.doi.org/10.1016/0092-8674(93)90403-D.
49. Zhou A, Paranjape J, Brown TL, Nie H, Naik S, Dong B, Chang A, Trapp B, Fairchild R, Colmenares C, Silverman RH. 1997. Interferon action and apoptosis are defective in mice devoid of 2',5\'-oligoadenylate-dependent RNase L. EMBO J. 16:6355-6363. http://dx.doi.org/10.1093/emboj/16.21.6355.
50. Ezelle HJ, Hassel BA. 2012. Pathologic effects of RNase-L dysregulation in immunity and proliferative control. Front. Biosci. (Schol. Ed.) 4:767-786. http://dx.doi.org/10.2741/298.
51. Chakrabarti A, Jha BK, Silverman RH. 2011. New insights into the role of RNase L in innate immunity. J. Interferon Cytokine Res. 31:49-57. http://dx.doi.org/10.1089/jir.2010.0120.
52. Li XL, Ezelle HJ, Kang TJ, Zhang L, Shirey KA, Harro J, Hasday JD, Mohapatra SK, Crasta OR, Vogel SN, Cross AS, Hassel BA. 2008. An essential role for the antiviral endoribonuclease, RNase-L, in antibacterial immunity. Proc. Natl. Acad. Sci. U. S. A. 105:20816-20821. http://dx.doi.org/10.1073/pnas.0807265105.
53. Kraus J, Ling AK, Hamm S, Voigt K, Oschmann P, Engelhardt B. 2004. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann. Neurol. 56:192-205. http://dx.doi.org/10.1002/ana.20161.
54. LeMessurier KS, Hacker H, Chi L, Tuomanen E, Redecke V. 2013. Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung. PLoS Pathog. 9:e1003727. http://dx.doi.org/10.1371/journal.ppat.1003727.
55. Nisa S, Hazen TH, Assatourian L, Nougayrede JP, Rasko DA, Donnenberg MS. 2013. In vitro evolution of an archetypal enteropathogenic Escherichia coli strain. J. Bacteriol. 195:4476-4483. http://dx.doi.org/10.1128/JB.00704-13.
56. Eswarappa SM, Janice J, Balasundaram SV, Chakravortty D. 2013. Non-neutral evolution in non-LEE-encoded type III effectors of attaching and effacing Escherichia coli. Microbes Infect. 15:147-151. http://dx.doi.org/10.1016/j.micinf.2012.10.015.
57. Pearson JS, Giogha C, Ong SY, Kennedy CL, Kelly M, Robinson KS, Lung TW, Mansell A, Riedmaier P, Oates CV, Zaid A, Muhlen S, Crepin VF, Marches O, Ang CS, Williamson NA, O'Reilly LA, Bankovacki A, Nachbur U, Infusini G, Webb AI, Silke J, Strasser A, Frankel G, Hartland EL. 2013. A type III effector antagonizes death receptor signalling during bacterial gut infection. Nature 501:247-251. http://dx.doi.org/10.1038/nature12524.
58. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U. S. A. 97:6640-6645. http://dx.doi.org/10.1073/pnas.120163297.
59. Gonzalez-Navajas JM, Lee J, David M, Raz E. 2012. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12:125-135. http://dx.doi.org/10.1038/nri3133.
60. Zhang Q, Li Q, Wang C, Liu X, Li N, Li J. 2010. Enteropathogenic Escherichia coli changes distribution of occludin and ZO-1 in tight junction membrane microdomains in vivo. Microb. Pathog. 48:28-34. http://dx.doi.org/10.1016/j.micpath.2009.10.002.
61. Canil C, Rosenshine I, Ruschkowski S, Donnenberg MS, Kaper JB, Finlay BB. 1993. Enteropathogenic Escherichia coli decreases the transepithelial electrical resistance of polarized epithelial monolayers. Infect. Immun. 61:2755-2762.
62. Minagar A, Long A, Ma T, Jackson TH, Kelley RE, Ostanin DV, Sasaki M, Warren AC, Jawahar A, Cappell B, Alexander JS. 2003. Interferon (IFN)-beta 1a and IFN-beta 1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier. Endothelium 10:299-307. http://dx.doi.org/10.1080/714007544.
63. Li Q, Zhang Q, Wang C, Li N, Li J. 2008. Invasion of enteropathogenic Escherichia coli into host cells through epithelial tight junctions. FEBS J. 275:6022-6032. http://dx.doi.org/10.1111/j.1742-4658.2008.06731.x.
64. Glotfelty LG, Hecht GA. 2012. Enteropathogenic E. coli effectors EspG1/G2 disrupt tight junctions: new roles and mechanisms. Ann. N. Y. Acad. Sci. 1258:149-158. http://dx.doi.org/10.1111/j.1749-6632.2012.06563.x.
65. Zahavi EE, Lieberman JA, Donnenberg MS, Nitzan M, Baruch K, Rosenshine I, Turner JR, Melamed-Book N, Feinstein N, Zlotkin-Rivkin E, Aroeti B. 2011. Bundle-forming pilus retraction enhances enteropathogenic Escherichia coli infectivity. Mol. Biol. Cell 22:2436-2447. http://dx.doi.org/10.1091/mbc.E11-01-0001.
66. Ruchaud-Sparagano MH, Maresca M, Kenny B. 2007. Enteropathogenic Escherichia coli (EPEC) inactivate innate immune responses prior to compromising epithelial barrier function. Cell. Microbiol. 9:1909-1921. http://dx.doi.org/10.1111/j.1462-5822.2007.00923.x.
67. Silverman RH. 2007. A scientific journey through the 2-5A/RNase L system. Cytokine Growth Factor Rev. 18:381-388. http://dx.doi.org/10.1016/j.cytogfr.2007.06.012.
68. Li XL, Ezelle HJ, Hsi TY, Hassel BA. 2011. A central role for RNA in the induction and biological activities of type 1 interferons. Wiley Interdiscip Rev. RNA 2:58-78. http://dx.doi.org/10.1002/wrna.32.
69. Malathi K, Saito T, Crochet N, Barton DJ, Gale M, Jr, Silverman RH. 2010. RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP. RNA 16:2108-2119. http://dx.doi.org/10.1261/rna.2244210.
70. Silverman RH. 2007. Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. J. Virol. 81: 12720-12729. http://dx.doi.org/10.1128/JVI.01471-07.
71. Silverman RH, Skehel JJ, James TC, Wreschner DH, Kerr IM. 1983. rRNA cleavage as an index of ppp(A2'p)nA activity in interferon-treated encephalomyocarditis virus-infected cells. J. Virol. 46:1051-1055.
72. Cerf-Bensussan N, Gaboriau-Routhiau V. 2010. The immune system and the gut microbiota: friends or foes? Nat. Rev. Immunol. 10:735-744. http://dx.doi.org/10.1038/nri2850.
73. Brown EM, Sadarangani M, Finlay BB. 2013. The role of the immune system in governing host-microbe interactions in the intestine. Nat. Immunol. 14:660-667. http://dx.doi.org/10.1038/ni.2611.
74. Sham HP, Shames SR, Croxen MA, Ma C, Chan JM, Khan MA, Wickham ME, Deng W, Finlay BB, Vallance BA. 2011. Attaching and effacing bacterial effector NleC suppresses epithelial inflammatory responses by inhibiting NF-kappaB and p38 mitogen-activated protein kinase activation. Infect. Immun. 79:3552-3562. http://dx.doi.org/10.1128/IAI.05033-11.
75. Vossenkamper A, Marches O, Fairclough PD, Warnes G, Stagg AJ, Lindsay JO, Evans PC, Luong LE, Croft ANM, Naik S, Frankel G, MacDonald TT. 2010. Inhibition of NF-kappaB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE. J. Immunol. 185:4118-4127. http://dx.doi.org/10.4049/jimmunol.1000500.
76. Symons A, Beinke S, Ley SC. 2006. MAP kinase kinase kinases and innate immunity. Trends Immunol. 27:40-48. http://dx.doi.org/10.1016/j.it.2005.11.007.
77. Hennessy EJ, Parker AE, O'Neill LA. 2010. Targeting Toll-like receptors: emerging therapeutics? Nat. Rev. Drug Discov. 9:293-307. http://dx.doi.org/10.1038/nrd3203.
78. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, Gaestel M. 1999. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat. Cell Biol. 1:94-97. http://dx.doi.org/10.1038/10061.
79. Li XL, Blackford JA, Hassel BA. 1998. RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J. Virol. 72:2752-2759.
80. Andersen JB, Mazan-Mamczarz K, Zhan M, Gorospe M, Hassel BA. 2009. Ribosomal protein mRNAs are primary targets of regulation in RNase-L-induced senescence. RNA Biol. 6:305-315. http://dx.doi.org/10.4161/rna.6.3.8526.
81. Yi X, Zeng C, Liu H, Chen X, Zhang P, Yun BS, Jin G, Zhou A. 2013. Lack of RNase L attenuates macrophage functions. PLoS One 8:e81269. http://dx.doi.org/10.1371/journal.pone.0081269.
82. Townsend HL, Jha BK, Han JQ, Maluf NK, Silverman RH, Barton DJ. 2008. A viral RNA competitively inhibits the antiviral endoribonuclease domain of RNase L. RNA 14:1026-1036. http://dx.doi.org/10.1261/rna.958908.
83. Sato A, Naito T, Hiramoto A, Goda K, Omi T, Kitade Y, Sasaki T, Matsuda A, Fukushima M, Wataya Y, Kim HS. 2010. Association of RNase L with a Ras GTPase-activating-like protein IQGAP1 in mediating the apoptosis of a human cancer cell-line. FEBS J. 277:4464-4473. http://dx.doi.org/10.1111/j.1742-4658.2010.07833.x.
84. Brown MD, Bry L, Li Z, Sacks DB. 2008. Actin pedestal formation by enteropathogenic Escherichia coli is regulated by IQGAP1, calcium, and calmodulin. J. Biol. Chem. 283:35212-35222. http://dx.doi.org/10.1074/jbc.M803477200.
85. Li G, Xiang Y, Sabapathy K, Silverman RH. 2004. An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase. J. Biol. Chem. 279:1123-1131. http://dx.doi.org/10.1074/jbc.M305893200.
86. Iordanov MS, Wong J, Newton DL, Rybak SM, Bright RK, Flavell RA, Davis RJ, Magun BE. 2000. Differential requirement for the stressactivated protein kinase/c-Jun NH(2)-terminal kinase in RNA damageinduced apoptosis in primary and in immortalized fibroblasts. Mol. Cell Biol. Res. Commun. 4:122-128. http://dx.doi.org/10.1006/mcbr.2000.0266.
87. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ. 1999. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol. Cell. Biol. 19:4311-4323.
88. Brooks SA, Blackshear PJ. 2013. Tristetraprolin (TTP): interactions with mRNA and proteins, and current thoughts on mechanisms of action. Biochim. Biophys. Acta 1829:666-679. http://dx.doi.org/10.1016/j.bbagrm.2013.02.003.
89. Brennan-Laun SE, Ezelle HJ, Li XL, Hassel BA. 2014. RNase-L control of cellular mRNAs: roles in biologic functions and mechanisms of substrate targeting. J. Interferon Cytokine Res. 34:275-288. http://dx.doi.org/10.1089/jir.2013.0147.
90. Al-Haj L, Blackshear PJ, Khabar KS. 2012. Regulation of p21/CIP1/WAF-1 mediated cell-cycle arrest by RNase L and tristetraprolin, and involvement of AU-rich elements. Nucleic Acids Res. 40:7739-7752. http://dx.doi.org/10.1093/nar/gks545.
91. Brook M, Tchen CR, Santalucia T, McIlrath J, Arthur JS, Saklatvala J, Clark AR. 2006. Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways. Mol. Cell. Biol. 26:2408-2418. http://dx.doi.org/10.1128/MCB.26.6.2408-2418.2006.
92. Tchen CR, Brook M, Saklatvala J, Clark AR. 2004. The stability of tristetraprolin mRNA is regulated by mitogen-activated protein kinase p38 and by tristetraprolin itself. J. Biol. Chem. 279:32393-32400. http://dx.doi.org/10.1074/jbc.M402059200.
93. Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD, Radzioch D, Clark AR, Blackshear PJ, Kotlyarov A, Gaestel M. 2006. Mitogenactivated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol. Cell. Biol. 26:2399-2407. http://dx.doi.org/10.1128/MCB.26.6.2399-2407.2006.
94. Sauer I, Schaljo B, Vogl C, Gattermeier I, Kolbe T, Muller M, Blackshear PJ, Kovarik P. 2006. Interferons limit inflammatory responses by induction of tristetraprolin. Blood 107:4790-4797. http://dx.doi.org/10.1182/blood-2005-07-3058.
95. Kovarik P, Sauer I, Schaljo B. 2007. Molecular mechanisms of the anti-inflammatory functions of interferons. Immunobiology 212:895-901. http://dx.doi.org/10.1016/j.imbio.2007.09.011.
96. Simonovic I, Rosenberg J, Koutsouris A, Hecht G. 2000. Enteropathogenic Escherichia coli dephosphorylates and dissociates occludin from intestinal epithelial tight junctions. Cell. Microbiol. 2:305-315. http://dx.doi.org/10.1046/j.1462-5822.2000.00055.x.
97. Weflen AW, Alto NM, Hecht GA. 2009. Tight junctions and enteropathogenic E. coli. Ann. N. Y. Acad. Sci. 1165:169-174. http://dx.doi.org/10.1111/j.1749-6632.2009.04060.x.
98. Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, Chapman R, Hertzog PJ. 2013. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 41:D1040-D1046. http://dx.doi.org/10.1093/nar/gks1215.
99. Wilkins C, Woodward J, Lau DT, Barnes A, Joyce M, McFarlane N, McKeating JA, Tyrrell DL, Gale M, Jr. 2013. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 57:461-469. http://dx.doi.org/10.1002/hep.26066.
100. Stalnikowicz R, Goder K, Karmeli F, Fiocchi C, Rachmilewitz D. 1985. (2'-5')oligo adenylate synthetase activity in leucocytes of patients with inflammatory bowel disease. Gut 26:556-561. http://dx.doi.org/10.1136/gut.26.6.556.
101. Ting JP, Duncan JA, Lei Y. 2010. How the noninflammasome NLRs function in the innate immune system. Science 327:286-290. http://dx.doi.org/10.1126/science.1184004.
102. Dugan JW, Albor A, David L, Fowlkes J, Blackledge MT, Martin TM, Planck SR, Rosenzweig HL, Rosenbaum JT, Davey MP. 2009. Nucleotide oligomerization domain-2 interacts with 2'-5'-oligoadenylate synthetase type 2 and enhances RNase-L function in THP-1 cells. Mol. Immunol. 47:560-566. http://dx.doi.org/10.1016/j.molimm.2009.09.025.
103. Siddiqui MA, Malathi K. 2012. RNase L induces autophagy via c-Jun N-terminal kinase and double-stranded RNA-dependent protein kinase signaling pathways. J. Biol. Chem. 287:43651-43664. http://dx.doi.org/10.1074/jbc.M112.399964.
104. Chakrabarti A, Ghosh PK, Banerjee S, Gaughan C, Silverman RH. 2012. RNase L triggers autophagy in response to viral infections. J. Virol. 86:11311-11321. http://dx.doi.org/10.1128/JVI.00270-12.